Haemato-oncology clinical trials

Clinical trials are an important part of improving treatment for patients.

Academic and commercial trials are run through the Haemato-oncology Unit. Trials that are currently recruiting are listed below under each disease category.

Please email us for more information about our haemato-oncology clinical trials.

Acute leukaemias

Acute myeloid leukaemia (AML) trials

  • IDH1 inhibitor study for adults with AML with IDH1 mutation, either relapsed or refractory to conventional treatment or for those unsuitable for conventional treatment at presentation.
  • Trial of MDM2 antagonist in combination with intensive chemotherapy for relapsed/refractory AML in fit adults
  • AML19 for untreated patients aged 18-60 years with AML. Looking at one vs two doses of gemtuzumab ozogamicin with standard chemotherapy
  • AML18 for untreated patients aged over 60 years with AML. Looking at one vs two doses of gemtuzumab ozogamicin with standard chemotherapy

Acute lymphoblastic leukaemia (ALL) trials

  • UKALL2011 trial for young adults aged 18-24 years with untreated ALL, looking at different doses of steroids and high dose methotrexate
  • MEK inhibitor trial for relapsed/refractory acute lymphoblastic leukaemia with RAS-pathway mutations in adults.

Chronic lymphoid leukaemias

  • Randomised clinical trial comparing R-FC to R-Ibrutinib in treatment naïve CLL patients with intact TP53
  • Randomised clinical trial comparing Ibrutinib to Acalabrutinib in patients with previously treated CLL with ATM or TP53 loss

Lymphoma

  • A dose-finding study of single agent idelalisib in the treatment of double-refractory follicular lymphoma
  • A clinical trial of ibrutinib, lenalidomide and rituximab in patients with relapsed/refractory DLBCL

Myelodysplastic syndromes and other myeloid disorders

For patients with low blood counts of uncertain cause we have a gene sequencing study to test whether any genes are mutated.

Myeloma

  • An immunotherapy trial for patients with relapsed myeloma, combining daratumumab with a checkpoint inhibitor. Patients who do not respond to this combination go on to receive pomalidomide and dexamethasone in addition
  • A dose-finding study of a next generation thalidomide analogue
  • MUK7 – a randomised study comparing pomalidomide and dexamethasone with pomalidomide, dexamethasone and cyclophosphamide in patients with relapsed myeloma
  • MUK8 – a randomised study comparing cyclophosphamide and dexamethasone with ixazomib, cyclophosphamide and dexamethasone in patients with relapsed myeloma
  • iTIMM – an imaging study for newly diagnosed patients with myeloma that requires therapy which will include a stem cell transplant. Patients undergo a PET/CT scan and whole body diffusion weighted MRI at diagnosis, and then a further MRI after initial therapy and again after transplant